

Tari A King

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8905409/publications.pdf>

Version: 2024-02-01

151
papers

11,065
citations

117625

34
h-index

32842

100
g-index

155
all docs

155
docs citations

155
times ranked

20454
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2022, 29, 686-696.	1.5	11
2	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1660-1667.	1.5	14
3	Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2022, 29, 972-980.	1.5	12
4	Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation. <i>Annals of Surgical Oncology</i> , 2022, 29, 1670-1679.	1.5	9
5	ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1668-1669.	1.5	0
6	How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3764-3771.	1.5	6
7	Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis. <i>Cancer Research</i> , 2022, 82, P2-13-02-P2-13-02.	0.9	2
8	Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial. <i>Cancer Research</i> , 2022, 82, P3-18-05-P3-18-05.	0.9	0
9	Abstract P3-04-03: The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study. <i>Cancer Research</i> , 2022, 82, P3-04-03-P3-04-03.	0.9	0
10	Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial. <i>Cancer Research</i> , 2022, 82, PD9-01-PD9-01.	0.9	0
11	ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node?. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
12	Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4103-4114.	1.5	7
13	ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
14	Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 417-427.	2.5	11
15	Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 4181-4194.	1.5	1
16	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
17	De-escalating axillary surgery in early-stage breast cancer. <i>Breast</i> , 2022, 62, S43-S49.	2.2	22
18	ASO Visual Abstract: Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
19	ASO Visual Abstract: Race and Site of Care Impact Treatment Delays for Older Women with Non-Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0
20	Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	0
21	Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3361-3364.	1.6	14
22	Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2022, 29, 7674-7682.	1.5	2
23	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 7696-7702.	1.5	2
24	Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage Iâ€“III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7726-7736.	1.5	5
25	Reply to Comment on Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4053-4053.	1.5	0
26	The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). <i>Annals of Surgical Oncology</i> , 2021, 28, 2573-2578.	1.5	27
27	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. <i>Modern Pathology</i> , 2021, 34, 875-882.	5.5	18
28	Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines. <i>Journal of Clinical Oncology</i> , 2021, 39, 178-189.	1.6	39
29	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 815-821.	2.5	6
30	Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1358-1367.	1.5	29
31	Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. <i>Annals of Surgical Oncology</i> , 2021, 28, 5015-5038.	1.5	31
32	ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1368-1369.	1.5	2
33	Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. <i>Oncology</i> , 2021, 35, 77-83.	0.5	7
34	Arm Morbidity After Local Therapy for Young Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6071-6082.	1.5	7
35	Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. <i>Annals of Surgical Oncology</i> , 2021, 28, 7404-7409.	1.5	9
36	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€“Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1744-1750.	6.3	7

#	ARTICLE	IF	CITATIONS
37	Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 7347-7355.	1.5	6
38	ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. <i>Annals of Surgical Oncology</i> , 2021, 28, 465-466.	1.5	2
39	ASO Visual Abstract: Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2021, 28, 585-586.	1.5	2
40	Neoadjuvant Endocrine Therapy in Clinical Practice. <i>JAMA Oncology</i> , 2021, 7, 1700.	7.1	23
41	Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. <i>JAMA Surgery</i> , 2021, 156, e213758.	4.3	18
42	ASO Visual Abstract: Optimizing Axillary Management in Clinical T1â€“2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2021, 28, 702-702.	1.5	2
43	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. <i>Journal of the National Cancer Institute</i> , 2021, 113, 355-359.	6.3	10
44	The Tyrerâ€“Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS. <i>Annals of Surgical Oncology</i> , 2020, 27, 736-740.	1.5	29
45	The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 377-385.	2.5	3
46	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Danaâ€“Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
47	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366.	1.5	5
48	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020, 27, 2229-2237.	1.5	6
49	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERBB3 alterations. <i>Modern Pathology</i> , 2020, 33, 1287-1297.	5.5	19
50	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	7.1	51
51	Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1844-1851.	1.5	10
52	ASO Author Reflections: Breast Cancer Risk Assessment in Women with LCISâ€“More Work Is Needed. <i>Annals of Surgical Oncology</i> , 2020, 27, 741-742.	1.5	0
53	Multidisciplinary considerations in the treatment of tripleâ€“negative breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 432-442.	329.8	7
54	Patient preferences for locoregional therapy in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 291-309.	2.5	13

#	ARTICLE	IF	CITATIONS
55	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, 434-447e2.	0.5	24
56	Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 35.	5.2	27
57	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.8	24
58	Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. <i>Breast Cancer Research</i> , 2020, 22, 40.	5.0	33
59	The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3393-3401.	1.5	14
60	American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. <i>Annals of Diagnostic Pathology</i> , 2020, 45, 151481.	1.3	23
61	Incorporating Patient-Reported Outcome Measures into Breast Surgical Oncology: Advancing Toward Value-Based Care. <i>Oncologist</i> , 2020, 25, 384-390.	3.7	16
62	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 599-605.	2.5	7
63	Development and Validation of the BREAST-Q Breast-Conserving Therapy Module. <i>Annals of Surgical Oncology</i> , 2020, 27, 2238-2247.	1.5	22
64	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 207-217.	2.5	17
65	Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. <i>Journal of Clinical Oncology</i> , 2020, 38, 2273-2280.	1.6	5
66	The effect of modifiable risk factors on breast cancer aggressiveness among black and white women. <i>American Journal of Surgery</i> , 2019, 218, 689-694.	1.8	5
67	Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3517-3525.	1.5	29
68	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4264-4271.	1.5	19
69	Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach. <i>Annals of Surgical Oncology</i> , 2019, 26, 4326-4336.	1.5	28
70	Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 229-237.	2.5	7
71	Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3846-3855.	1.5	19
72	Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3502-3509.	1.5	61

#	ARTICLE	IF	CITATIONS
73	SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 16.	5.2	48
74	Benefit of regional anaesthesia on postoperative pain following mastectomy: the influence of catastrophising. <i>British Journal of Anaesthesia</i> , 2019, 123, e293-e302.	3.4	19
75	Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come. <i>Annals of Surgical Oncology</i> , 2019, 26, 1173-1175.	1.5	11
76	Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. <i>Advances in Anatomic Pathology</i> , 2019, 26, 221-234.	4.3	22
77	Lobular Carcinomas <i>in Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	7.0	44
78	Preoperative Psychosocial and Psychophysical Phenotypes as Predictors of Acute Pain Outcomes After Breast Surgery. <i>Journal of Pain</i> , 2019, 20, 540-556.	1.4	51
79	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 55-61.	1.5	36
80	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 667-677.	2.5	19
81	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.9	2
82	Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER) Medicare Registry. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 287-293.	2.5	8
83	How do age and molecular subtypes impact surgical decisions?. <i>Breast Cancer Management</i> , 2018, 7, BMT04.	0.2	2
84	Statin Use and Breast Cancer Prognosis in Black and White Women. <i>Hormones and Cancer</i> , 2018, 9, 55-61.	4.9	2
85	Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 555-566.	2.5	23
86	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	5.1	37
87	Lobular Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 81-94.	1.5	36
88	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
89	Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. <i>JAMA Surgery</i> , 2018, 153, 1145.	4.3	12
90	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. <i>Oncogene</i> , 2018, 37, 5101-5114.	5.9	22

#	ARTICLE	IF	CITATIONS
91	Surgeon Variability and Factors Predicting for Reoperation Following Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 2573-2578.	1.5	26
92	The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2612-2619.	1.5	14
93	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	1.5	17
94	Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3541-3547.	1.5	47
95	Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. <i>Annals of Surgical Oncology</i> , 2018, 25, 3527-3534.	1.5	13
96	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	30.7	111
97	Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017, 24, 2509-2517.	1.5	35
98	New Insights on the Role of Surgery for the Breast Primary Tumor in Patients Presenting With Stage IV Disease. <i>Current Breast Cancer Reports</i> , 2017, 9, 137-147.	1.0	1
99	Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 411-420.	2.5	38
100	Biallelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	4.5	43
101	Targeted Therapy and Local Control: The Dynamic Duo. <i>Annals of Surgical Oncology</i> , 2017, 24, 3110-3112.	1.5	0
102	Age, molecular subtypes and local therapy decision-making. <i>Breast</i> , 2017, 34, S70-S77.	2.2	9
103	Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. <i>Annals of Surgical Oncology</i> , 2017, 24, 698-704.	1.5	39
104	Alcohol consumption and breast tumor gene expression. <i>Breast Cancer Research</i> , 2017, 19, 108.	5.0	23
105	Implementation of Surgeon-Initiated Gene Expression Profile Testing (OncoDX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. <i>Journal of Oncology Practice</i> , 2017, 13, e815-e820.	2.5	14
106	Reply to L. Del Mastro and A. Prat. <i>Journal of Clinical Oncology</i> , 2017, 35, 1139-1139.	1.6	0
107	Contralateral prophylactic mastectomy and quality of life: answering the unanswered questions?. <i>Gland Surgery</i> , 2016, 5, 261-262.	1.1	6
108	Trends and controversies in multidisciplinary care of the patient with breast cancer. <i>Current Problems in Surgery</i> , 2016, 53, 559-595.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Clonal relationships between lobular carcinoma in situ and other breast malignancies. Breast Cancer Research, 2016, 18, 66.	5.0	32
110	Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?. Annals of Surgical Oncology, 2016, 23, 2229-2234.	1.5	14
111	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 2016, 23, 3467-3474.	1.5	232
112	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) â€“Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2416-2427.	1.6	112
113	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
114	Multifocality and Bilaterality of Lobular Carcinoma In Situ in Women with Synchronous Breast Malignancies. American Journal of Clinical Pathology, 2016, 146, .	0.7	0
115	Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment, 2016, 157, 587-596.	2.5	33
116	Timeliness in Breast Cancer Treatmentâ€”The Sooner, the Better. JAMA Oncology, 2016, 2, 302.	7.1	16
117	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. Molecular Oncology, 2016, 10, 360-370.	4.6	41
118	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
119	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq1 1 0.784314 82BT /Over	0.7	82
120	Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2016, 23, 1537-1542.	1.5	16
121	Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Annals of Surgical Oncology, 2016, 23, 471-476.	1.5	13
122	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. Annals of Surgical Oncology, 2016, 23, 257-264.	1.5	121
123	Optimal surgical management for high-risk populations. Breast, 2015, 24, S91-S95.	2.2	7
124	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Molecular Oncology, 2015, 9, 772-782.	4.6	32
125	Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nature Reviews Clinical Oncology, 2015, 12, 335-343.	27.6	164
126	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	27.8	3,688

#	ARTICLE	IF	CITATIONS
127	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	28.9	1,485
128	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	21.4	139
129	Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2015, 33, 3945-3952.	1.6	153
130	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. <i>Journal of Clinical Oncology</i> , 2014, 32, 3330-3336.	1.6	80
131	Incorporating the Results of the American College of Surgeons Oncology Group Z0011 Trial into Clinical Practice. <i>Current Breast Cancer Reports</i> , 2014, 6, 17-23.	1.0	2
132	Age and molecular subtypes: Impact on surgical decisions. <i>Journal of Surgical Oncology</i> , 2014, 110, 8-14.	1.7	13
133	Lobular Neoplasia. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 487-503.	1.5	27
134	Is there a role for routine screening MRI in women with LCIS?. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 445-453.	2.5	53
135	Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 507-507.	1.6	4
136	Triple-Negative Breast Cancer. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-1.	1.2	7
137	Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. <i>Breast Cancer Research</i> , 2012, 14, R103.	5.0	38
138	Cadherin-catenin complex dissociation in lobular neoplasia of the breast. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 641-652.	2.5	47
139	Is There a Low-Grade Precursor Pathway in Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2012, 19, 1115-1121.	1.5	20
140	Occult Malignancy in Patients Undergoing Contralateral Prophylactic Mastectomy. <i>Annals of Surgery</i> , 2011, 254, 2-7.	4.2	32
141	Selecting local therapy in the young breast cancer patient. <i>Journal of Surgical Oncology</i> , 2011, 103, 330-336.	1.7	8
142	Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2158-2164.	1.6	298
143	Is pleomorphic lobular carcinoma really a distinct clinical entity?. <i>Journal of Surgical Oncology</i> , 2008, 98, 314-317.	1.7	63
144	Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?. <i>Cancer</i> , 2008, 112, 1214-1221.	4.1	43

#	ARTICLE	IF	CITATIONS
145	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2510-2518.	1.5	82
146	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. <i>Cancer Research</i> , 2004, 64, 5051-5053.	0.9	51
147	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. <i>Annals of Surgical Oncology</i> , 2004, 11, 535-541.	1.5	67
148	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events. <i>Cancer</i> , 2004, 101, 926-933.	4.1	52
149	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , .	7.1	51
150	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	2.5	1
151	Surgical Decision-making in Early-Stage Breast Cancerâ€™Trends and Opportunities. <i>JAMA Surgery</i> , 0, , .	4.3	0